Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
NEW YORK, Aug. 15, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) between January 14, 2016 and July 26, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Shanawaz v. Intellipharmaceutics International Inc., et al. (Case No. 1:17-cv-05761) in the USDC for the Southern District of New York. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra-sbm/intellipharmaceutics-international-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Intellipharmaceutics failed to conduct a human abuse liability study to support its Rexista New Drug Application (“NDA”); (2) the Company did not include abuse-deterrent studies conducted to support abuse-deterrent label claims related to abuse of the drug by various pathways; (3) the Company was not submitting sufficient data to support approval of the NDA; and (4) as a result, Defendants’ statements about Intellipharmaceutics’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
On July 27, 2017, shares of Intellipharmaceutics fell when the FDA released a report disclosing that “The safety information collected in the pharmacokinetic studies was of limited value…”
If you suffered a loss in Intellipharmaceutics you have until September 29, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
